nodes	percent_of_prediction	percent_of_DWPC	metapath
Candesartan—CYP2C8—Sorafenib—thyroid cancer	0.12	0.359	CbGbCtD
Candesartan—CYP2C9—Sorafenib—thyroid cancer	0.0839	0.25	CbGbCtD
Candesartan—ABCB1—Sorafenib—thyroid cancer	0.0814	0.243	CbGbCtD
Candesartan—ABCB1—Doxorubicin—thyroid cancer	0.0494	0.147	CbGbCtD
Candesartan—Nephropathy—Vandetanib—thyroid cancer	0.0218	0.0386	CcSEcCtD
Candesartan—Serum creatinine increased—Vandetanib—thyroid cancer	0.0168	0.0298	CcSEcCtD
Candesartan—Bilirubin total increased—Epirubicin—thyroid cancer	0.0129	0.0228	CcSEcCtD
Candesartan—Bilirubin total increased—Doxorubicin—thyroid cancer	0.0119	0.0211	CcSEcCtD
Candesartan—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.0115	0.123	CbGpPWpGaD
Candesartan—Blood bilirubin increased—Vandetanib—thyroid cancer	0.011	0.0194	CcSEcCtD
Candesartan—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00863	0.0928	CbGpPWpGaD
Candesartan—Gastroenteritis—Vandetanib—thyroid cancer	0.00848	0.015	CcSEcCtD
Candesartan—Rhabdomyolysis—Sorafenib—thyroid cancer	0.0079	0.014	CcSEcCtD
Candesartan—Telmisartan—PPARG—thyroid cancer	0.00779	1	CrCbGaD
Candesartan—Cardiac failure—Vandetanib—thyroid cancer	0.00771	0.0137	CcSEcCtD
Candesartan—Hyponatraemia—Vandetanib—thyroid cancer	0.00755	0.0134	CcSEcCtD
Candesartan—Blood bilirubin increased—Sorafenib—thyroid cancer	0.00739	0.0131	CcSEcCtD
Candesartan—Blood creatinine increased—Vandetanib—thyroid cancer	0.00704	0.0125	CcSEcCtD
Candesartan—Bronchitis—Vandetanib—thyroid cancer	0.00625	0.0111	CcSEcCtD
Candesartan—Neutropenia—Vandetanib—thyroid cancer	0.00608	0.0108	CcSEcCtD
Candesartan—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00604	0.0107	CcSEcCtD
Candesartan—Hyperglycaemia—Vandetanib—thyroid cancer	0.00586	0.0104	CcSEcCtD
Candesartan—Renal failure—Vandetanib—thyroid cancer	0.0057	0.0101	CcSEcCtD
Candesartan—Cardiac failure congestive—Sorafenib—thyroid cancer	0.00559	0.00991	CcSEcCtD
Candesartan—Haematuria—Vandetanib—thyroid cancer	0.00553	0.00979	CcSEcCtD
Candesartan—Epistaxis—Vandetanib—thyroid cancer	0.00547	0.00969	CcSEcCtD
Candesartan—Sinusitis—Vandetanib—thyroid cancer	0.00544	0.00964	CcSEcCtD
Candesartan—Kidney function abnormal—Epirubicin—thyroid cancer	0.00534	0.00947	CcSEcCtD
Candesartan—Haemoglobin—Vandetanib—thyroid cancer	0.00523	0.00927	CcSEcCtD
Candesartan—Haemorrhage—Vandetanib—thyroid cancer	0.0052	0.00922	CcSEcCtD
Candesartan—Cardiac failure—Sorafenib—thyroid cancer	0.0052	0.00921	CcSEcCtD
Candesartan—Urinary tract disorder—Vandetanib—thyroid cancer	0.00514	0.00911	CcSEcCtD
Candesartan—Urethral disorder—Vandetanib—thyroid cancer	0.0051	0.00904	CcSEcCtD
Candesartan—Hyponatraemia—Sorafenib—thyroid cancer	0.00509	0.00903	CcSEcCtD
Candesartan—Kidney function abnormal—Doxorubicin—thyroid cancer	0.00494	0.00876	CcSEcCtD
Candesartan—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00469	0.0504	CbGpPWpGaD
Candesartan—AGTR1—Arf6 signaling events—TSHR—thyroid cancer	0.00457	0.0491	CbGpPWpGaD
Candesartan—Mental disorder—Vandetanib—thyroid cancer	0.00456	0.00808	CcSEcCtD
Candesartan—Malnutrition—Vandetanib—thyroid cancer	0.00453	0.00803	CcSEcCtD
Candesartan—Transaminases increased—Epirubicin—thyroid cancer	0.00424	0.00752	CcSEcCtD
Candesartan—Serum creatinine increased—Epirubicin—thyroid cancer	0.0042	0.00744	CcSEcCtD
Candesartan—Neutropenia—Sorafenib—thyroid cancer	0.0041	0.00727	CcSEcCtD
Candesartan—Cough—Vandetanib—thyroid cancer	0.00395	0.007	CcSEcCtD
Candesartan—Transaminases increased—Doxorubicin—thyroid cancer	0.00393	0.00696	CcSEcCtD
Candesartan—Hypertension—Vandetanib—thyroid cancer	0.00391	0.00693	CcSEcCtD
Candesartan—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00388	0.00689	CcSEcCtD
Candesartan—Chest pain—Vandetanib—thyroid cancer	0.00386	0.00683	CcSEcCtD
Candesartan—Arthralgia—Vandetanib—thyroid cancer	0.00386	0.00683	CcSEcCtD
Candesartan—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00385	0.00683	CcSEcCtD
Candesartan—Renal failure—Sorafenib—thyroid cancer	0.00384	0.00681	CcSEcCtD
Candesartan—Anxiety—Vandetanib—thyroid cancer	0.00384	0.00681	CcSEcCtD
Candesartan—Myocardial infarction—Sorafenib—thyroid cancer	0.00383	0.00679	CcSEcCtD
Candesartan—Epistaxis—Sorafenib—thyroid cancer	0.00369	0.00653	CcSEcCtD
Candesartan—Thrombocytopenia—Vandetanib—thyroid cancer	0.00362	0.00641	CcSEcCtD
Candesartan—AGTR1—Arf6 trafficking events—TSHR—thyroid cancer	0.00361	0.0388	CbGpPWpGaD
Candesartan—Haemoglobin—Sorafenib—thyroid cancer	0.00353	0.00625	CcSEcCtD
Candesartan—Haemorrhage—Sorafenib—thyroid cancer	0.00351	0.00622	CcSEcCtD
Candesartan—Urinary tract disorder—Sorafenib—thyroid cancer	0.00347	0.00614	CcSEcCtD
Candesartan—Albuminuria—Epirubicin—thyroid cancer	0.00346	0.00613	CcSEcCtD
Candesartan—Urethral disorder—Sorafenib—thyroid cancer	0.00344	0.0061	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00337	0.00597	CcSEcCtD
Candesartan—Paraesthesia—Vandetanib—thyroid cancer	0.00332	0.00588	CcSEcCtD
Candesartan—Dyspnoea—Vandetanib—thyroid cancer	0.00329	0.00584	CcSEcCtD
Candesartan—Dyspepsia—Vandetanib—thyroid cancer	0.00325	0.00577	CcSEcCtD
Candesartan—Albuminuria—Doxorubicin—thyroid cancer	0.0032	0.00567	CcSEcCtD
Candesartan—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00319	0.00566	CcSEcCtD
Candesartan—Fatigue—Vandetanib—thyroid cancer	0.00319	0.00565	CcSEcCtD
Candesartan—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00312	0.0335	CbGpPWpGaD
Candesartan—Mental disorder—Sorafenib—thyroid cancer	0.00307	0.00545	CcSEcCtD
Candesartan—Malnutrition—Sorafenib—thyroid cancer	0.00305	0.00541	CcSEcCtD
Candesartan—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00302	0.00536	CcSEcCtD
Candesartan—Abdominal pain—Vandetanib—thyroid cancer	0.00292	0.00518	CcSEcCtD
Candesartan—Body temperature increased—Vandetanib—thyroid cancer	0.00292	0.00518	CcSEcCtD
Candesartan—UGT1A3—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00286	0.0307	CbGpPWpGaD
Candesartan—Anaemia—Sorafenib—thyroid cancer	0.00282	0.005	CcSEcCtD
Candesartan—Angioedema—Sorafenib—thyroid cancer	0.00279	0.00495	CcSEcCtD
Candesartan—Hyperuricaemia—Epirubicin—thyroid cancer	0.00278	0.00493	CcSEcCtD
Candesartan—Leukopenia—Sorafenib—thyroid cancer	0.00273	0.00485	CcSEcCtD
Candesartan—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00273	0.00484	CcSEcCtD
Candesartan—Cough—Sorafenib—thyroid cancer	0.00267	0.00472	CcSEcCtD
Candesartan—Asthenia—Vandetanib—thyroid cancer	0.00265	0.0047	CcSEcCtD
Candesartan—Hypertension—Sorafenib—thyroid cancer	0.00264	0.00467	CcSEcCtD
Candesartan—Blood uric acid increased—Epirubicin—thyroid cancer	0.00263	0.00466	CcSEcCtD
Candesartan—Pruritus—Vandetanib—thyroid cancer	0.00261	0.00463	CcSEcCtD
Candesartan—Arthralgia—Sorafenib—thyroid cancer	0.0026	0.00461	CcSEcCtD
Candesartan—Myalgia—Sorafenib—thyroid cancer	0.0026	0.00461	CcSEcCtD
Candesartan—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00258	0.00457	CcSEcCtD
Candesartan—Hyperkalaemia—Epirubicin—thyroid cancer	0.00254	0.0045	CcSEcCtD
Candesartan—Diarrhoea—Vandetanib—thyroid cancer	0.00253	0.00448	CcSEcCtD
Candesartan—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00253	0.00448	CcSEcCtD
Candesartan—UGT1A3—Metapathway biotransformation—CHST14—thyroid cancer	0.00252	0.0271	CbGpPWpGaD
Candesartan—AGTR1—Peptide GPCRs—TSHR—thyroid cancer	0.00251	0.027	CbGpPWpGaD
Candesartan—Dizziness—Vandetanib—thyroid cancer	0.00244	0.00433	CcSEcCtD
Candesartan—Thrombocytopenia—Sorafenib—thyroid cancer	0.00244	0.00433	CcSEcCtD
Candesartan—Blood urea increased—Epirubicin—thyroid cancer	0.00244	0.00432	CcSEcCtD
Candesartan—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00243	0.00431	CcSEcCtD
Candesartan—Vomiting—Vandetanib—thyroid cancer	0.00235	0.00416	CcSEcCtD
Candesartan—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00235	0.00416	CcSEcCtD
Candesartan—Rash—Vandetanib—thyroid cancer	0.00233	0.00413	CcSEcCtD
Candesartan—Dermatitis—Vandetanib—thyroid cancer	0.00233	0.00413	CcSEcCtD
Candesartan—Headache—Vandetanib—thyroid cancer	0.00232	0.0041	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00227	0.00403	CcSEcCtD
Candesartan—Blood urea increased—Doxorubicin—thyroid cancer	0.00226	0.004	CcSEcCtD
Candesartan—Dyspnoea—Sorafenib—thyroid cancer	0.00222	0.00394	CcSEcCtD
Candesartan—Nausea—Vandetanib—thyroid cancer	0.0022	0.00389	CcSEcCtD
Candesartan—Dyspepsia—Sorafenib—thyroid cancer	0.00219	0.00389	CcSEcCtD
Candesartan—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00215	0.00381	CcSEcCtD
Candesartan—Fatigue—Sorafenib—thyroid cancer	0.00215	0.00381	CcSEcCtD
Candesartan—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00207	0.00366	CcSEcCtD
Candesartan—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00204	0.00361	CcSEcCtD
Candesartan—CYP2C8—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00201	0.0216	CbGpPWpGaD
Candesartan—Urticaria—Sorafenib—thyroid cancer	0.00198	0.00351	CcSEcCtD
Candesartan—Body temperature increased—Sorafenib—thyroid cancer	0.00197	0.00349	CcSEcCtD
Candesartan—Abdominal pain—Sorafenib—thyroid cancer	0.00197	0.00349	CcSEcCtD
Candesartan—Renal impairment—Epirubicin—thyroid cancer	0.00197	0.00349	CcSEcCtD
Candesartan—Cardiac failure—Epirubicin—thyroid cancer	0.00192	0.0034	CcSEcCtD
Candesartan—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00191	0.00339	CcSEcCtD
Candesartan—Hyponatraemia—Epirubicin—thyroid cancer	0.00188	0.00334	CcSEcCtD
Candesartan—Renal impairment—Doxorubicin—thyroid cancer	0.00182	0.00323	CcSEcCtD
Candesartan—Asthenia—Sorafenib—thyroid cancer	0.00179	0.00317	CcSEcCtD
Candesartan—Cardiac failure—Doxorubicin—thyroid cancer	0.00178	0.00315	CcSEcCtD
Candesartan—Pruritus—Sorafenib—thyroid cancer	0.00176	0.00313	CcSEcCtD
Candesartan—Blood creatinine increased—Epirubicin—thyroid cancer	0.00176	0.00311	CcSEcCtD
Candesartan—Hyponatraemia—Doxorubicin—thyroid cancer	0.00174	0.00309	CcSEcCtD
Candesartan—Diarrhoea—Sorafenib—thyroid cancer	0.00171	0.00302	CcSEcCtD
Candesartan—Dizziness—Sorafenib—thyroid cancer	0.00165	0.00292	CcSEcCtD
Candesartan—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00164	0.0176	CbGpPWpGaD
Candesartan—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00162	0.00288	CcSEcCtD
Candesartan—Vomiting—Sorafenib—thyroid cancer	0.00159	0.00281	CcSEcCtD
Candesartan—Angina pectoris—Epirubicin—thyroid cancer	0.00158	0.0028	CcSEcCtD
Candesartan—Rash—Sorafenib—thyroid cancer	0.00157	0.00279	CcSEcCtD
Candesartan—Dermatitis—Sorafenib—thyroid cancer	0.00157	0.00278	CcSEcCtD
Candesartan—Headache—Sorafenib—thyroid cancer	0.00156	0.00277	CcSEcCtD
Candesartan—Bronchitis—Epirubicin—thyroid cancer	0.00156	0.00276	CcSEcCtD
Candesartan—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.00155	0.0166	CbGpPWpGaD
Candesartan—Neutropenia—Epirubicin—thyroid cancer	0.00152	0.00269	CcSEcCtD
Candesartan—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00151	0.00267	CcSEcCtD
Candesartan—Nausea—Sorafenib—thyroid cancer	0.00148	0.00262	CcSEcCtD
Candesartan—Hyperglycaemia—Epirubicin—thyroid cancer	0.00146	0.00259	CcSEcCtD
Candesartan—Angina pectoris—Doxorubicin—thyroid cancer	0.00146	0.00259	CcSEcCtD
Candesartan—Bronchitis—Doxorubicin—thyroid cancer	0.00144	0.00256	CcSEcCtD
Candesartan—Renal failure—Epirubicin—thyroid cancer	0.00142	0.00252	CcSEcCtD
Candesartan—Neutropenia—Doxorubicin—thyroid cancer	0.0014	0.00248	CcSEcCtD
Candesartan—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00139	0.00247	CcSEcCtD
Candesartan—Haematuria—Epirubicin—thyroid cancer	0.00138	0.00244	CcSEcCtD
Candesartan—Epistaxis—Epirubicin—thyroid cancer	0.00136	0.00242	CcSEcCtD
Candesartan—Sinusitis—Epirubicin—thyroid cancer	0.00136	0.0024	CcSEcCtD
Candesartan—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00135	0.0024	CcSEcCtD
Candesartan—Agranulocytosis—Epirubicin—thyroid cancer	0.00135	0.00239	CcSEcCtD
Candesartan—Renal failure—Doxorubicin—thyroid cancer	0.00131	0.00233	CcSEcCtD
Candesartan—Haemoglobin—Epirubicin—thyroid cancer	0.0013	0.00231	CcSEcCtD
Candesartan—AGTR1—GPCR ligand binding—CALCB—thyroid cancer	0.0013	0.014	CbGpPWpGaD
Candesartan—Rhinitis—Epirubicin—thyroid cancer	0.0013	0.0023	CcSEcCtD
Candesartan—Hepatitis—Epirubicin—thyroid cancer	0.0013	0.0023	CcSEcCtD
Candesartan—Haemorrhage—Epirubicin—thyroid cancer	0.0013	0.0023	CcSEcCtD
Candesartan—Pharyngitis—Epirubicin—thyroid cancer	0.00129	0.00228	CcSEcCtD
Candesartan—Urinary tract disorder—Epirubicin—thyroid cancer	0.00128	0.00227	CcSEcCtD
Candesartan—Oedema peripheral—Epirubicin—thyroid cancer	0.00128	0.00226	CcSEcCtD
Candesartan—Haematuria—Doxorubicin—thyroid cancer	0.00127	0.00226	CcSEcCtD
Candesartan—Urethral disorder—Epirubicin—thyroid cancer	0.00127	0.00225	CcSEcCtD
Candesartan—Epistaxis—Doxorubicin—thyroid cancer	0.00126	0.00223	CcSEcCtD
Candesartan—Sinusitis—Doxorubicin—thyroid cancer	0.00125	0.00222	CcSEcCtD
Candesartan—Agranulocytosis—Doxorubicin—thyroid cancer	0.00125	0.00221	CcSEcCtD
Candesartan—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.00121	0.013	CbGpPWpGaD
Candesartan—Haemoglobin—Doxorubicin—thyroid cancer	0.00121	0.00214	CcSEcCtD
Candesartan—Rhinitis—Doxorubicin—thyroid cancer	0.0012	0.00213	CcSEcCtD
Candesartan—Haemorrhage—Doxorubicin—thyroid cancer	0.0012	0.00213	CcSEcCtD
Candesartan—Hepatitis—Doxorubicin—thyroid cancer	0.0012	0.00213	CcSEcCtD
Candesartan—Pharyngitis—Doxorubicin—thyroid cancer	0.00119	0.00211	CcSEcCtD
Candesartan—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00119	0.0021	CcSEcCtD
Candesartan—Oedema peripheral—Doxorubicin—thyroid cancer	0.00118	0.0021	CcSEcCtD
Candesartan—Urethral disorder—Doxorubicin—thyroid cancer	0.00118	0.00208	CcSEcCtD
Candesartan—Mental disorder—Epirubicin—thyroid cancer	0.00114	0.00201	CcSEcCtD
Candesartan—Malnutrition—Epirubicin—thyroid cancer	0.00113	0.002	CcSEcCtD
Candesartan—Back pain—Epirubicin—thyroid cancer	0.00109	0.00194	CcSEcCtD
Candesartan—Mental disorder—Doxorubicin—thyroid cancer	0.00105	0.00186	CcSEcCtD
Candesartan—Malnutrition—Doxorubicin—thyroid cancer	0.00104	0.00185	CcSEcCtD
Candesartan—Anaemia—Epirubicin—thyroid cancer	0.00104	0.00185	CcSEcCtD
Candesartan—Vertigo—Epirubicin—thyroid cancer	0.00101	0.0018	CcSEcCtD
Candesartan—Leukopenia—Epirubicin—thyroid cancer	0.00101	0.00179	CcSEcCtD
Candesartan—Back pain—Doxorubicin—thyroid cancer	0.00101	0.00179	CcSEcCtD
Candesartan—UGT1A3—NRF2 pathway—SLC5A5—thyroid cancer	0.00101	0.0109	CbGpPWpGaD
Candesartan—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.00101	0.0108	CbGpPWpGaD
Candesartan—Palpitations—Epirubicin—thyroid cancer	0.000998	0.00177	CcSEcCtD
Candesartan—Cough—Epirubicin—thyroid cancer	0.000985	0.00175	CcSEcCtD
Candesartan—Hypertension—Epirubicin—thyroid cancer	0.000975	0.00173	CcSEcCtD
Candesartan—Anaemia—Doxorubicin—thyroid cancer	0.000965	0.00171	CcSEcCtD
Candesartan—Myalgia—Epirubicin—thyroid cancer	0.000961	0.0017	CcSEcCtD
Candesartan—Arthralgia—Epirubicin—thyroid cancer	0.000961	0.0017	CcSEcCtD
Candesartan—Chest pain—Epirubicin—thyroid cancer	0.000961	0.0017	CcSEcCtD
Candesartan—Anxiety—Epirubicin—thyroid cancer	0.000958	0.0017	CcSEcCtD
Candesartan—Vertigo—Doxorubicin—thyroid cancer	0.000938	0.00166	CcSEcCtD
Candesartan—Leukopenia—Doxorubicin—thyroid cancer	0.000935	0.00166	CcSEcCtD
Candesartan—Palpitations—Doxorubicin—thyroid cancer	0.000923	0.00164	CcSEcCtD
Candesartan—AGTR1—Peptide ligand-binding receptors—SST—thyroid cancer	0.000917	0.00986	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.000917	0.00986	CbGpPWpGaD
Candesartan—Cough—Doxorubicin—thyroid cancer	0.000912	0.00162	CcSEcCtD
Candesartan—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000906	0.00974	CbGpPWpGaD
Candesartan—Thrombocytopenia—Epirubicin—thyroid cancer	0.000902	0.0016	CcSEcCtD
Candesartan—Hypertension—Doxorubicin—thyroid cancer	0.000902	0.0016	CcSEcCtD
Candesartan—Tachycardia—Epirubicin—thyroid cancer	0.000899	0.00159	CcSEcCtD
Candesartan—Hyperhidrosis—Epirubicin—thyroid cancer	0.000891	0.00158	CcSEcCtD
Candesartan—Arthralgia—Doxorubicin—thyroid cancer	0.000889	0.00158	CcSEcCtD
Candesartan—Myalgia—Doxorubicin—thyroid cancer	0.000889	0.00158	CcSEcCtD
Candesartan—Chest pain—Doxorubicin—thyroid cancer	0.000889	0.00158	CcSEcCtD
Candesartan—Anxiety—Doxorubicin—thyroid cancer	0.000886	0.00157	CcSEcCtD
Candesartan—Hypotension—Epirubicin—thyroid cancer	0.000861	0.00153	CcSEcCtD
Candesartan—UGT1A3—NRF2 pathway—RXRA—thyroid cancer	0.000848	0.00912	CbGpPWpGaD
Candesartan—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000846	0.00909	CbGpPWpGaD
Candesartan—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000842	0.00905	CbGpPWpGaD
Candesartan—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000839	0.00149	CcSEcCtD
Candesartan—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000835	0.00148	CcSEcCtD
Candesartan—Tachycardia—Doxorubicin—thyroid cancer	0.000832	0.00147	CcSEcCtD
Candesartan—Paraesthesia—Epirubicin—thyroid cancer	0.000827	0.00147	CcSEcCtD
Candesartan—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000824	0.00146	CcSEcCtD
Candesartan—Dyspnoea—Epirubicin—thyroid cancer	0.000821	0.00146	CcSEcCtD
Candesartan—Somnolence—Epirubicin—thyroid cancer	0.000819	0.00145	CcSEcCtD
Candesartan—Dyspepsia—Epirubicin—thyroid cancer	0.000811	0.00144	CcSEcCtD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000807	0.00867	CbGpPWpGaD
Candesartan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000803	0.00864	CbGpPWpGaD
Candesartan—Hypotension—Doxorubicin—thyroid cancer	0.000797	0.00141	CcSEcCtD
Candesartan—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000795	0.00141	CcSEcCtD
Candesartan—Fatigue—Epirubicin—thyroid cancer	0.000794	0.00141	CcSEcCtD
Candesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000791	0.00851	CbGpPWpGaD
Candesartan—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000789	0.00848	CbGpPWpGaD
Candesartan—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000777	0.00138	CcSEcCtD
Candesartan—Paraesthesia—Doxorubicin—thyroid cancer	0.000766	0.00136	CcSEcCtD
Candesartan—Dyspnoea—Doxorubicin—thyroid cancer	0.00076	0.00135	CcSEcCtD
Candesartan—Somnolence—Doxorubicin—thyroid cancer	0.000758	0.00134	CcSEcCtD
Candesartan—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000753	0.00134	CcSEcCtD
Candesartan—Dyspepsia—Doxorubicin—thyroid cancer	0.00075	0.00133	CcSEcCtD
Candesartan—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000746	0.00802	CbGpPWpGaD
Candesartan—UGT1A3—Biological oxidations—RXRA—thyroid cancer	0.000744	0.008	CbGpPWpGaD
Candesartan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000736	0.0013	CcSEcCtD
Candesartan—AGTR1—GPCR downstream signaling—CALCB—thyroid cancer	0.000736	0.00791	CbGpPWpGaD
Candesartan—Fatigue—Doxorubicin—thyroid cancer	0.000735	0.0013	CcSEcCtD
Candesartan—UGT1A3—NRF2 pathway—NRG1—thyroid cancer	0.000734	0.00789	CbGpPWpGaD
Candesartan—Urticaria—Epirubicin—thyroid cancer	0.000732	0.0013	CcSEcCtD
Candesartan—Abdominal pain—Epirubicin—thyroid cancer	0.000728	0.00129	CcSEcCtD
Candesartan—Body temperature increased—Epirubicin—thyroid cancer	0.000728	0.00129	CcSEcCtD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.000724	0.00779	CbGpPWpGaD
Candesartan—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000697	0.00124	CcSEcCtD
Candesartan—Urticaria—Doxorubicin—thyroid cancer	0.000677	0.0012	CcSEcCtD
Candesartan—Body temperature increased—Doxorubicin—thyroid cancer	0.000674	0.00119	CcSEcCtD
Candesartan—Abdominal pain—Doxorubicin—thyroid cancer	0.000674	0.00119	CcSEcCtD
Candesartan—AGTR1—Signaling by GPCR—CALCB—thyroid cancer	0.000668	0.00718	CbGpPWpGaD
Candesartan—Asthenia—Epirubicin—thyroid cancer	0.000661	0.00117	CcSEcCtD
Candesartan—Pruritus—Epirubicin—thyroid cancer	0.000652	0.00116	CcSEcCtD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000633	0.00681	CbGpPWpGaD
Candesartan—Diarrhoea—Epirubicin—thyroid cancer	0.00063	0.00112	CcSEcCtD
Candesartan—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000629	0.00676	CbGpPWpGaD
Candesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000615	0.00662	CbGpPWpGaD
Candesartan—Asthenia—Doxorubicin—thyroid cancer	0.000612	0.00108	CcSEcCtD
Candesartan—Dizziness—Epirubicin—thyroid cancer	0.000609	0.00108	CcSEcCtD
Candesartan—Pruritus—Doxorubicin—thyroid cancer	0.000603	0.00107	CcSEcCtD
Candesartan—AGTR1—GPCR ligand binding—TSHR—thyroid cancer	0.000603	0.00648	CbGpPWpGaD
Candesartan—Vomiting—Epirubicin—thyroid cancer	0.000586	0.00104	CcSEcCtD
Candesartan—Diarrhoea—Doxorubicin—thyroid cancer	0.000583	0.00103	CcSEcCtD
Candesartan—Rash—Epirubicin—thyroid cancer	0.000581	0.00103	CcSEcCtD
Candesartan—Dermatitis—Epirubicin—thyroid cancer	0.00058	0.00103	CcSEcCtD
Candesartan—Headache—Epirubicin—thyroid cancer	0.000577	0.00102	CcSEcCtD
Candesartan—Dizziness—Doxorubicin—thyroid cancer	0.000564	0.000999	CcSEcCtD
Candesartan—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000559	0.00601	CbGpPWpGaD
Candesartan—Nausea—Epirubicin—thyroid cancer	0.000547	0.00097	CcSEcCtD
Candesartan—UGT1A3—Metabolism—MINPP1—thyroid cancer	0.000547	0.00588	CbGpPWpGaD
Candesartan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000545	0.00586	CbGpPWpGaD
Candesartan—Vomiting—Doxorubicin—thyroid cancer	0.000542	0.000961	CcSEcCtD
Candesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—thyroid cancer	0.000539	0.00579	CbGpPWpGaD
Candesartan—Rash—Doxorubicin—thyroid cancer	0.000538	0.000953	CcSEcCtD
Candesartan—Dermatitis—Doxorubicin—thyroid cancer	0.000537	0.000952	CcSEcCtD
Candesartan—Headache—Doxorubicin—thyroid cancer	0.000534	0.000947	CcSEcCtD
Candesartan—AGTR1—GPCR ligand binding—PTCH1—thyroid cancer	0.000512	0.00551	CbGpPWpGaD
Candesartan—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000512	0.0055	CbGpPWpGaD
Candesartan—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00051	0.00548	CbGpPWpGaD
Candesartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000509	0.00547	CbGpPWpGaD
Candesartan—Nausea—Doxorubicin—thyroid cancer	0.000506	0.000898	CcSEcCtD
Candesartan—AGTR1—GPCR ligand binding—SST—thyroid cancer	0.000469	0.00504	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—NDUFA13—thyroid cancer	0.000465	0.005	CbGpPWpGaD
Candesartan—AGTR1—GPCR ligand binding—CALCA—thyroid cancer	0.000451	0.00485	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000445	0.00479	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—CHST14—thyroid cancer	0.000437	0.0047	CbGpPWpGaD
Candesartan—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000419	0.00451	CbGpPWpGaD
Candesartan—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000415	0.00446	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CALCB—thyroid cancer	0.000395	0.00424	CbGpPWpGaD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000394	0.00424	CbGpPWpGaD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000377	0.00405	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TRIM33—thyroid cancer	0.000374	0.00402	CbGpPWpGaD
Candesartan—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000361	0.00388	CbGpPWpGaD
Candesartan—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000356	0.00383	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—HPGD—thyroid cancer	0.000352	0.00379	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—TSHR—thyroid cancer	0.000341	0.00366	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—TSHR—thyroid cancer	0.000309	0.00332	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000308	0.00331	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000304	0.00327	CbGpPWpGaD
Candesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000294	0.00316	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000288	0.00309	CbGpPWpGaD
Candesartan—CYP2C8—Biological oxidations—RXRA—thyroid cancer	0.000271	0.00291	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—SST—thyroid cancer	0.000265	0.00285	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000263	0.00283	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000262	0.00281	CbGpPWpGaD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00026	0.00279	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—CALCA—thyroid cancer	0.000255	0.00274	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TCF7L1—thyroid cancer	0.00025	0.00268	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—CHST14—thyroid cancer	0.000246	0.00265	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—SST—thyroid cancer	0.000241	0.00259	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000234	0.00252	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—CALCA—thyroid cancer	0.000232	0.00249	CbGpPWpGaD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000224	0.0024	CbGpPWpGaD
Candesartan—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.00022	0.00237	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000217	0.00233	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—CDK1—thyroid cancer	0.00021	0.00225	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—TPR—thyroid cancer	0.000202	0.00217	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PRKAR1A—thyroid cancer	0.000199	0.00214	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—MINPP1—thyroid cancer	0.000199	0.00214	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—HPGD—thyroid cancer	0.000198	0.00213	CbGpPWpGaD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.00019	0.00204	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TSHR—thyroid cancer	0.000183	0.00196	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.00018	0.00193	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—MINPP1—thyroid cancer	0.000173	0.00186	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—MEN1—thyroid cancer	0.000172	0.00185	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000169	0.00182	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—MINPP1—thyroid cancer	0.000162	0.00174	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000161	0.00173	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CHST14—thyroid cancer	0.000159	0.00171	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PTCH1—thyroid cancer	0.000155	0.00167	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—SLC5A5—thyroid cancer	0.000151	0.00163	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NDUFA13—thyroid cancer	0.000147	0.00158	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—SST—thyroid cancer	0.000142	0.00153	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CHST14—thyroid cancer	0.000139	0.00149	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NDUFA13—thyroid cancer	0.000138	0.00148	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000137	0.00147	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000137	0.00147	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CALCA—thyroid cancer	0.000137	0.00147	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000135	0.00145	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CHST14—thyroid cancer	0.000129	0.00139	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—HPGD—thyroid cancer	0.000128	0.00138	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—RXRA—thyroid cancer	0.000127	0.00137	CbGpPWpGaD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000127	0.00136	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CDK1—thyroid cancer	0.000124	0.00133	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—TPR—thyroid cancer	0.000114	0.00123	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PRKAR1A—thyroid cancer	0.000112	0.00121	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—HPGD—thyroid cancer	0.000112	0.0012	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000108	0.00116	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—HPGD—thyroid cancer	0.000104	0.00112	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000104	0.00112	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000102	0.0011	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000102	0.00109	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—NRG1—thyroid cancer	9.94e-05	0.00107	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	9.73e-05	0.00105	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	9.39e-05	0.00101	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TERT—thyroid cancer	8.92e-05	0.000959	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.61e-05	0.000926	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—HIF1A—thyroid cancer	8.53e-05	0.000917	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—SLC5A5—thyroid cancer	8.53e-05	0.000917	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.46e-05	0.00091	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PPARG—thyroid cancer	8.03e-05	0.000864	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	7.99e-05	0.000859	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—NRAS—thyroid cancer	7.52e-05	0.000808	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—TPR—thyroid cancer	7.36e-05	0.000791	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	7.24e-05	0.000778	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	7.21e-05	0.000775	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—RXRA—thyroid cancer	7.17e-05	0.00077	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—BRAF—thyroid cancer	7.07e-05	0.00076	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	6.97e-05	0.000749	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.56e-05	0.000706	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—KRAS—thyroid cancer	6.47e-05	0.000696	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—TPR—thyroid cancer	6.41e-05	0.000689	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	6.41e-05	0.000689	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PTGS2—thyroid cancer	6.32e-05	0.000679	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PRKAR1A—thyroid cancer	6.31e-05	0.000678	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—TPR—thyroid cancer	5.99e-05	0.000644	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	5.89e-05	0.000634	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PTEN—thyroid cancer	5.51e-05	0.000593	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—SLC5A5—thyroid cancer	5.51e-05	0.000592	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—HRAS—thyroid cancer	5.5e-05	0.000591	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.41e-05	0.000582	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—AKT1—thyroid cancer	5.35e-05	0.000575	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.34e-05	0.000574	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.16e-05	0.000555	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CCND1—thyroid cancer	5.16e-05	0.000554	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PTEN—thyroid cancer	4.98e-05	0.000535	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—AKT1—thyroid cancer	4.86e-05	0.000522	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—SLC5A5—thyroid cancer	4.8e-05	0.000516	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—RXRA—thyroid cancer	4.63e-05	0.000498	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PPARG—thyroid cancer	4.53e-05	0.000486	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.5e-05	0.000484	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—SLC5A5—thyroid cancer	4.48e-05	0.000482	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—NRAS—thyroid cancer	4.44e-05	0.000477	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.2e-05	0.000452	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—RXRA—thyroid cancer	4.03e-05	0.000434	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—KRAS—thyroid cancer	3.82e-05	0.000411	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—RXRA—thyroid cancer	3.77e-05	0.000405	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.66e-05	0.000394	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PTGS2—thyroid cancer	3.56e-05	0.000383	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TP53—thyroid cancer	3.4e-05	0.000365	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—HRAS—thyroid cancer	3.25e-05	0.000349	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—AKT1—thyroid cancer	3.18e-05	0.000341	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PTEN—thyroid cancer	3.1e-05	0.000334	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PPARG—thyroid cancer	2.92e-05	0.000314	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—AKT1—thyroid cancer	2.87e-05	0.000308	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PPARG—thyroid cancer	2.55e-05	0.000274	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PPARG—thyroid cancer	2.38e-05	0.000256	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PTGS2—thyroid cancer	2.3e-05	0.000247	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PTEN—thyroid cancer	2.01e-05	0.000216	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PTGS2—thyroid cancer	2e-05	0.000215	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.87e-05	0.000201	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—AKT1—thyroid cancer	1.79e-05	0.000192	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PTEN—thyroid cancer	1.75e-05	0.000188	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PTEN—thyroid cancer	1.63e-05	0.000175	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—AKT1—thyroid cancer	1.16e-05	0.000124	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—AKT1—thyroid cancer	1.01e-05	0.000108	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—AKT1—thyroid cancer	9.41e-06	0.000101	CbGpPWpGaD
